Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsORALGeneric

PIPERAZINE CITRATE

PIPERAZINE CITRATE

Standard Dose
EQ 250MG BASE
Max Dose
Refer to approved labeling
Primary Use
Marketing status: Discontinued
Summary

Approval overview PIPERAZINE CITRATE is listed in Drugs@FDA under application 080874 (ANDA).

Marketing status: Discontinued Active ingredient PIPERAZINE CITRATE Form and strength TABLET;ORAL - EQ 250MG BASE Sponsor IMPAX LABS Submission history Latest submission status date: 1989-05-24 00:00:00.

Structured Monograph

Clinical summary

Approval overview PIPERAZINE CITRATE is listed in Drugs@FDA under application 080874 (ANDA). Marketing status: Discontinued Active ingredient PIPERAZINE CITRATE Form and strength TABLET;ORAL - EQ 250MG BASE Sponsor IMPAX LABS Submission history Latest submission status date: 1989-05-24 00:00:00. Submission type: SUPPL.

Monitoring

  • • Marketing status: Discontinued

Interaction Notes

  • No interaction notes stored yet.
PIPERAZINE CITRATE (PIPERAZINE CITRATE) | Drug Monograph | MedicHelpline